The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia
Open accessPublished version of a preprint
Abstract
Chimeric antigen receptor (CAR)–modified T cells with anti-CD19 specificity are a highly effective novel immune therapy for relapsed/refractory acute lymphoblastic leukemia. Cytokine release syndrome (CRS) is the most significant and life-threatening toxicity. To improve understanding of CRS, we measured cytokines and clinical biomarkers in 51 CTL019-treated patients. Peak levels of 24 cytokines, including IFNγ, IL6, sgp130, and sIL6R, in the first month after infusion were highly associated with severe CRS. Using regression modeling, we could accurately predict which patients would develop severe CRS with a signature composed of three cytokines. Results were validated in an independent cohort. Changes in serum biochemical markers, including C-reactive protein and ferritin, were associated with CRS but failed to predict development of severe CRS. These comprehensive profiling data provide novel insights into CRS biology and, importantly, represent the first data that can accurately predict which patients have a high probability of becoming critically ill. Significance: CRS is the most common severe toxicity seen after CAR T-cell treatment. We developed models that can accurately predict which patients are likely to develop severe CRS before they become critically ill, which improves understanding of CRS biology and may guide future cytokine-directed therapy. Cancer Discov; 6(6); 664–79. ©2016 AACR. See related commentary by Rouce and Heslop, p. 579. This article is highlighted in the In This Issue feature, p. 561
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most severe of these immune-related adverse events (irAEs) are cytokine release syndrome (CRS) and neurotoxicity, most prominently described in patients treated with CAR-T-cells [6–11].”
From Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm (2021) · cites this paper as [7]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Immune checkpoint blockade induces irAEs during short-term follow-up of some patients with cancer, though robust immune biomarkers correlating with adverse effects of therapy are still being investigated [1, 4, 7, 20–25].”
From Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm (2021) · cites this paper as [7]
Experimental — accuracy not yet measuredIn the citing paper
“Serum biomarkers, including glycoprotein 130 (gp130), interferon-γ, and interleukin-1–receptor antagonist (IL1RA), can be used to predict the severity of cytokine storm induced by CAR T-cell therapy”
From Cytokine storm (2020) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Simple Sequentially Rejective Multiple Test Procedure
(1979) · Scandinavian Journal of Statistics · doi:10.2307/4615733 · Cited by 21,526
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Self-citationChimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Self-citationChimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Self-citationLee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Self-citationEfficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514
Porter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729
Self-citationRose-John, S. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4989 · Cited by 1,040 · cited 3×
“In other IL6-mediated diseases, IL6 levels often go up and sIL6R levels either increase or decrease after treatment as the interaction between IL6R and IL6 is blocked (21, 23, 24).”
BackgroundSelf-citationBorowitz, M. J., Devidas, M., Hunger, S. P., Bowman, W. P., Carroll, A. J., Carroll, W. L., Linda, S. B., Martin, P. L., Pullen, D. J., Viswanatha, D. S., et al. (2008) · Blood · doi:10.1182/blood-2008-01-132837 · Cited by 841
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 1,000
Advancing CAR T-cell Therapies with Artificial Intelligence: Opportunities and Challenges
Luciani, F., Safavi, A., Guruprasad, P., Chen, L., & Ruella, M. (2025) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0240 · Cited by 33
Oncologic Emergencies—The Old, the New, and the Deadly
Thandra, K. C., Salah, Z., & Chawla, S. (2018) · Journal of Intensive Care Medicine · doi:10.1177/0885066618803863 · Cited by 33
Bastien, J.-P., Minguy, A., Davé, V. P., & Roy, D. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101306 · Cited by 35
Mastroianni, A., Greco, S., Apuzzo, G., Santis, S. D., Oriolo, C., Zanolini, A., Chidichimo, L., & Vangeli, V. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2020.100410 · Cited by 33
Amigues, I., Pearlman, A. H., Patel, A. M., Reid, P. D., Robinson, P. C., Sinha, R. R., Kim, A. H. J., Youngstein, T., Jayatilleke, A., & Konig, M. F. (2020) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1847084 · Cited by 33
Robust Antitumor Activity and Low Cytokine Production by Novel Humanized Anti-CD19 CAR T Cells
Dwivedi, A., Karulkar, A., Ghosh, S., Srinivasan, S., Kumbhar, B. V., Jaiswal, A. K., Kizhakeyil, A., Asija, S., Rafiq, A., Kumar, S., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0476 · Cited by 35
Otoukesh, S., Elmariah, H., Yang, D., Clark, M. C., Siraj, M., Ali, H., Mogili, K., Arslan, S., Nishihori, T., Nakamura, R., et al. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.11.012 · Cited by 33
CAR-T in the Treatment of Acute Myeloid Leukemia: Barriers and How to Overcome Them
Vanhooren, J., Dobbelaere, R., Derpoorter, C., Deneweth, L., Camp, L. V., Uyttebroeck, A., Moerloose, B. D., & Lammens, T. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000937 · Cited by 34
Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies
Ye, B., Stary, C. M., Qingping, G., Wang, Q., Zeng, Z. R., Jian, Z., Gu, L., & Xiong, X. (2017) · Journal of Immunology Research · doi:10.1155/2017/5210459 · Cited by 33
Unleash the power of the mighty T cells-basis of adoptive cellular therapy
Sukari, A. W., Abdallah, N. H., & Nagasaka, M. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.01.015 · Cited by 33
Mirzaei, H. R., Mirzaei, H., Namdar, A., Rahmati, M., Till, B. G., & Hadjati, J. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27519 · Cited by 32
Chimeric antigen receptor T‐cell therapy toxicities
Greenbaum, U., Kebriaei, P., Srour, S. A., Olson, A. L., Bashir, Q., Neelapu, S. S., Rezvani, K., & Shpall, E. J. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14403 · Cited by 32
The Application of CAR-T Cells in Haematological Malignancies
Skórka, K., Ostapińska, K., Malesa, A., & Giannopoulos, K. (2020) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-020-00599-x · Cited by 34
Interleukin-6 and cytokine release syndrome
Lee, E. Y., & Jakubovic, B. D. (2022) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2022.10.025 · Cited by 32
Mohan, M., Szabó, A., Patwari, A., Esselmann, J., Patel, T., Bachu, R., Rein, L., Janardan, A., Bhatlapenumarthi, V., Annyapu, E., et al. (2024) · Bone Marrow Transplantation · doi:10.1038/s41409-024-02233-2 · Cited by 31
Youssef, E. M., Weddle, K., Zimmerman, L., & Palmer, D. (2025) · Drug Safety · doi:10.1007/s40264-025-01596-9 · Cited by 31
Immunotherapy for ALL takes the world by storm
Teachey, D. T., & Hunger, S. P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.176 · Cited by 31
Self-citationYakoub‐Agha, I., Moreau, A., Ahmad, I., Borel, C., Hadhoum, N., Masouridi‐Levrat, S., Naudin, J., Nicolas‐Virelizier, E., Ouachée-Chardin, M., Platon, L., et al. (2019) · Bulletin du Cancer · doi:10.1016/j.bulcan.2018.12.001 · Cited by 34
Controlling Cytokine Release Syndrome to Harness the Full Potential of CAR-Based Cellular Therapy
Thakar, M. S., Kearl, T. J., & Malarkannan, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01529 · Cited by 32
Car-T Treatment for Hematological Malignancies
Atrash, S., Bano, K., Harrison, B. W., & Abdallah, A.-O. A. (2020) · Journal of Investigative Medicine · doi:10.1136/jim-2020-001290 · Cited by 32
Filgrastim associations with CAR T‐cell therapy
Gaut, D. L., Tang, K., Sim, M., Duong, T., Young, P. A., & Sasine, J. P. (2020) · International Journal of Cancer · doi:10.1002/ijc.33356 · Cited by 34
In vivo CART cell imaging: Paving the way for success in CART cell therapy
Sakemura, R. L., Can, İ., Siegler, E. L., & Kenderian, S. S. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.03.003 · Cited by 33
Immunological perspectives on the pathogenesis, diagnosis, prevention and treatment of COVID-19
Ni, Y., Alu, A., Hong, L., Wang, Y., Wu, M., & Wei, X. (2021) · Molecular Biomedicine · doi:10.1186/s43556-020-00015-y · Cited by 32
Sakemura, R. L., Bansal, A., Siegler, E. L., Hefazi, M., Yang, N., Khadka, R. H., Newsom, A. N., Hansen, M. J., Cox, M. J., Roman, C. M., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0901 · Cited by 33
Chang, J. C. H., Matsubara, D., Morgan, R. W., Diorio, C. J., Nadaraj, S., Teachey, D. T., Bassiri, H., Behrens, E. M., & Banerjee, A. N. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.021428 · Cited by 31
Self-citationLeonard, J. T., & Hayes‐Lattin, B. (2018) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-018-0462-x · Cited by 31
Agarwal, S., & June, C. H. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0473 · Cited by 30
Self-citationMontecinos, L., Eskew, J. D., & Smith, A. (2019) · Pharmaceuticals · doi:10.3390/ph12040144 · Cited by 30
Interleukin‑6 signaling blockade treatment for cytokine release syndrome in COVID‑19 (Review)
Chen, J., Zhang, L., Hou, H., Xu, L., & Ji, K. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.9456 · Cited by 30
Real-Time Monitoring of Biomolecules: Dynamic Response Limits of Affinity-Based Sensors
Lubken, R. M., de Jong, A. M., & Prins, M. W. J. (2022) · ACS Sensors · doi:10.1021/acssensors.1c02307 · Cited by 30
Drougkas, K., Karampinos, K. I., Karavolias, I., Koumprentziotis, I., Ploumaki, I., Triantafyllou, E., Trontzas, I. P., & Kotteas, E. A. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04547-4 · Cited by 30
Zhao, L., Yang, Y., Li, W., Li, T., & Gao, Q. (2018) · Immunotherapy · doi:10.2217/imt-2018-0025 · Cited by 30
Population-Based External Validation of the EASIX Scores to Predict CAR T-Cell-Related Toxicities
de Boer, J., Keijzer, K., Pennings, E. R. A., van Doesum, J. A., Spanjaart, A. M., Jak, M., Mutsaers, P., van Dorp, S., Vermaat, J. S. P., van der Poel, M., et al. (2023) · Cancers · doi:10.3390/cancers15225443 · Cited by 29
Zhang, P.-F., & Xie, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1362133 · Cited by 29
Cytokine Release Syndrome and Neurotoxicity Following CD19 CAR-T in B-Cell Lymphoma
Shouval, R., Strouse, C. S., Kim, S., Oloyede, T., Ahmed, S., Awan, F. T., Luan, D., Bachanová, V., Badar, T., Bar, M., et al. (2025) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2025.03.011 · Cited by 29
Sterner, R. M., & Kenderian, S. S. (2019) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000559 · Cited by 29
Targeted Cellular Micropharmacies: Cells Engineered for Localized Drug Delivery
Gardner, T. J., Bourne, C. M., Dacek, M. M., Kurtz, K. G., Malviya, M., Peraro, L., Silberman, P. C., Vogt, K. C., Unti, M. J., Brentjens, R. J., et al. (2020) · Cancers · doi:10.3390/cancers12082175 · Cited by 29
Kleen, T. O., Galdon, A. A., MacDonald, A. S., & Dalgleish, A. G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02059 · Cited by 29
Diagnosis of SARS-CoV-2 infection in the setting of the cytokine release syndrome
Azar, M. M., Shin, J. J., Kang, I., & Landry, M. L. (2020) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2020.1830760 · Cited by 30
Faulhaber, L. D., Phuong, A. Q., Hartsuyker, K. J., Cho, Y., Mand, K. K., Harper, S. D., Olson, A. K., Garden, G. A., Shih, A. Y., & Gust, J. (2021) · Brain Communications · doi:10.1093/braincomms/fcab309 · Cited by 31
Hadidi, S. A., Heslop, H. E., Brenner, M. K., & Suzuki, M. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.05.039 · Cited by 29
IL-6 Blockade in Cytokine Storm Syndromes
Barrett, D. M. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-59815-9_37 · Cited by 28
Self-citationChen, G. M., Azzam, A., Ding, Y., Barrett, D. M., Grupp, S. A., & Tan, K. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3888 · Cited by 28
Self-citation“Cytokine storm”, not only in COVID-19 patients. Mini-review
Lukán, N. (2020) · Immunology Letters · doi:10.1016/j.imlet.2020.09.007 · Cited by 29
Schöffski, P., Concin, N., Suárez, C., Subbiah, V., Ando, Y., Ruan, S., Wagner, J. P., Mansfield, K. G., Zhu, X., Origuchi, S., et al. (2021) · Oncology Research and Treatment · doi:10.1159/000518549 · Cited by 28
Early-drug development in the era of immuno-oncology: are we ready to face the challenges?
de Olza, M. O., Oliva, M., Hierro, C., Matos, I. G., Martín-Liberal, J., & Garralda, E. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy225 · Cited by 28
Chimeric Antigen Receptor T‐Cell Therapy Clinical Results in Pediatric and Young Adult B‐ALL
DiNofia, A. M., & Maude, S. L. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000279 · Cited by 29
Self-citationCytokine release syndrome in solid tumors
Synnott, D., O’Reilly, D., de Freitas, D. G., & Naidoo, J. (2025) · Cancer · doi:10.1002/cncr.70069 · Cited by 27
Li, L., Liu, J., Xu, M., Yu, H., Lv, C., Cao, F., Wang, Z., Fu, Y., Zhang, M., Meng, H., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2388-1 · Cited by 27
Neurologic Toxicities of Cancer Immunotherapies: a Review
Harrison, R. A., Tummala, S., & de Groot, J. (2020) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-020-01038-2 · Cited by 27
Davey, A. S., Call, M. E., & Call, M. J. (2020) · Cancers · doi:10.3390/cancers13010038 · Cited by 28
Checkpoint blockade toxicities: Insights into autoimmunity and treatment
Walsh, M. J., & Dougan, M. L. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101473 · Cited by 27
Emerging approaches for preventing cytokine release syndrome in CAR-T cell therapy
Balagopal, S., Sasaki, K., Kaur, P., Nikolaidi, M., & Ishihara, J. (2022) · Journal of Materials Chemistry B · doi:10.1039/d2tb00592a · Cited by 27
Su, M., Chen, L., Xie, L., Fleurie, A., Jonquieres, R., Cao, Q., Li, B., Liang, J. A., & Tang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1450173 · Cited by 27
Clinical and molecular dissection of CAR T cell resistance in pancreatic cancer
Aznar, M. A., Good, C. R., Barber-Rotenberg, J. S., Agarwal, S., Wilson, W. V., Watts, A., Zhang, Z., Gonzales, D. M., Donahue, G., Hwang, W.-T., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102301 · Cited by 30
Self-citationPrimary Bone Tumors: Challenges and Opportunities for CAR-T Therapies
Folkert, I. W., Devalaraja, S., Linette, G. P., WEBER, K. L., & Haldar, M. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3852 · Cited by 27
Clinical Pharmacology Perspectives for Adoptive Cell Therapies in Oncology
Huang, W., Li, J., Liao, M. Z., Liu, S. N., Yu, J., Jing, J., Kotani, N., Kamen, L. A., Guelman, S. A., & Miles, D. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2509 · Cited by 27
Walton, Z. E., Frigault, M. J., & Maus, M. V. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2340738 · Cited by 26
Sánchez-Moreno, I., Lasarte-Cía, A., Martín-Otal, C., Casares, N., Navarro, F. C., Gorraiz, M., Sarrión, P., Hervás‐Stubbs, S., Jordana-Urriza, L., Rodríguez-Madoz, J. R., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008572 · Cited by 25
Immune Effector Cell-associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)
Lee, J. C., Johnson, W. T., Hines, M., & Shah, N. N. (2025) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2025.02.005 · Cited by 27
Current Advances and Challenges in CAR-T Therapy for Hematological and Solid Tumors
Zhang, G., Bai, M., Du, H., Yuan, Y., Wang, Y., Fan, W., Zhu, H., Wu, D., He, P., & Xue, B. (2025) · ImmunoTargets and Therapy · doi:10.2147/itt.s519616 · Cited by 26
Immunotherapy in Pediatric Solid Tumors—A Systematic Review
Marayati, R., Quinn, C. H., & Beierle, E. A. (2019) · Cancers · doi:10.3390/cancers11122022 · Cited by 27
Management and Prevention of Cellular-Therapy-Related Toxicity: Early and Late Complications
Mucha, S. R., & Rajendram, P. (2023) · Current Oncology · doi:10.3390/curroncol30050378 · Cited by 26
Secondary hemophagocytic lymphohistiocytosis in children (Review)
Benevenuta, C., Mussinatto, I., Orsi, C., & Timeus, F. S. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.12122 · Cited by 26
Bindal, P., Patell, R. D., Chiasakul, T., Lauw, M. N., Ko, A., Wang, T., & Zwicker, J. I. (2024) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2024.03.021 · Cited by 26
Yoshikawa, T., Ito, Y., Wu, Z., Kasuya, H., Nakashima, T., Okamoto, S., Amaishi, Y., Zhang, H., Li, Y., Matsukawa, T., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101526 · Cited by 26
Recent advances in T‐cell immunotherapy for haematological malignancies
Rouce, R. H., Sharma, S., Huynh, M., & Heslop, H. E. (2016) · British Journal of Haematology · doi:10.1111/bjh.14470 · Cited by 25
Wang, T., Gao, L., Wang, Y., Zhu, W., Xu, L., Wang, Y., Yue, W., Tang, G., Chen, L., Chen, J., et al. (2020) · Immunotherapy · doi:10.2217/imt-2020-0075 · Cited by 26
Myers, R. M., DiNofia, A. M., Li, Y., Diorio, C., Liu, H., Wertheim, G. B. W., Fraietta, J. A., Gonzalez, V. E., Plesa, G., Siegel, D. L., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011549 · Cited by 24
Self-citationManagement of Cytokine Release Syndrome (CRS) following CAR T-cell therapy: a comprehensive review
Zhang, Y., & Han, W. (2025) · Clinical Cancer Bulletin · doi:10.1007/s44272-025-00044-0 · Cited by 25
New developments in immunotherapy for pediatric leukemia
Foster, J., & Maude, S. L. (2017) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000572 · Cited by 24
Self-citationJin, A., Feng, J., Wang, Z., Li, J., Hu, Y., Zhao, K., & Huang, H. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0412-1 · Cited by 24
CAR-T cell therapy: practical guide to routine laboratory monitoring
Selim, A. G., Minson, A. G., Blombery, P. A., Dickinson, M. J., Harrison, S. J., & Anderson, M. A. (2021) · Pathology · doi:10.1016/j.pathol.2021.02.002 · Cited by 24
Strategies Towards Antigen-Specific Treatments for Membranous Nephropathy
Köllner, S. M. S., Seifert, L., Zahner, G., & Tomas, N. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.822508 · Cited by 24
An Overview of CAR T Cell Mediated B Cell Maturation Antigen Therapy
Quazi, S. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.12.003 · Cited by 24
Ba, H., Dai, Z., Zhang, Z., Zhang, P., Yin, B., Wang, J., Li, Z., & Zhou, X. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003837 · Cited by 24
Safety of CAR-T Cell Therapy in Patients With Renal Failure/Acute Kidney Injury: Focused Review
Khan, I., Khan, N., Wolfson, N., Djebabria, K., Rehman, M. E. U., & Anwer, F. (2023) · Clinical Hematology International · doi:10.1007/s44228-023-00037-7 · Cited by 25
Marchal, E., Palard-Novello, X., Lhomme, F., Meyer, M.-É., Manson, G., Devillers, A., Marolleau, J., Houot, R., & Girard, A. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06427-6 · Cited by 24
Jambon, S., Sun, J., Barman, S., Muthugounder, S., Bito, X. R., Shadfar, A., Kovach, A. E., Wood, B. L., Manoharan, V. T., Morrissy, A. S., et al. (2024) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0258 · Cited by 24
Haase, I., Richter, J., Holzer, M., Fehse, B., Ruffer, N., Seibel, J., Berger, S. C., Gagelmann, N., Borie, D. C., Ayuk, F. A., et al. (2025) · Rheumatology · doi:10.1093/rheumatology/keaf190 · Cited by 23
Chimeric Antigen Receptor T-Cell Therapy
Ogba, N., Arwood, N. M., Bartlett, N. L., Bloom, M. G., Brown, P. A., Brown, C. E., Budde, E. L., Carlson, R. W., Farnia, S. H., Fry, T. J., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0073 · Cited by 23
Yoo, H. J., & Harapan, B. N. (2021) · Immunologic Research · doi:10.1007/s12026-021-09236-x · Cited by 25
Baumeister, S. H. C., Mohan, G. S., Elhaddad, A., & Lehmann, L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.841117 · Cited by 23
Chimeric antigen receptor T-cells for B-cell malignancies
Lichtman, E. I., & Dotti, G. (2017) · Translational research · doi:10.1016/j.trsl.2017.06.011 · Cited by 23
Füchsl, F., & Krackhardt, A. M. (2022) · Cells · doi:10.3390/cells11030410 · Cited by 24
Cardiovascular toxicities associated with novel cellular immune therapies
Munir, M., Sayed, A., Addison, D., & Epperla, N. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013849 · Cited by 27
Evolving strategies for addressing CAR T-cell toxicities
Rankin, A. W., Duncan, B. B., Allen, C., Silbert, S. K., & Shah, N. N. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10227-1 · Cited by 22
Nanoparticle-based strategy in CAR-T cell immunotherapy: challenges, implications, and perspectives
Shang, D., Zhou, Z., Shi, R., Wang, Z., Zhang, P., Fu, P., Li, H., Cheng, G., Qin, H., Xie, Z., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02476-7 · Cited by 26
Guo, H., Qian, L., & Cui, J. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2021.0087 · Cited by 24
Insights into Modern Therapeutic Approaches in Pediatric Acute Leukemias
Panuciak, K., Margas, M., Makowska, K., & Lejman, M. (2022) · Cells · doi:10.3390/cells11010139 · Cited by 22
Kast, J., Nozohouri, S., Zhou, D., Yago, M. R., Chen, P., Ahamadi, M., Dutta, S., & Upreti, V. V. (2022) · Clinical and Translational Science · doi:10.1111/cts.13349 · Cited by 23
Novel Immunotherapeutic Approaches to Treating HPV-Related Head and Neck Cancer
Saba, N. F., Pamulapati, S. V., Patel, B., Mody, M. D., Strojan, P., Takes, R. P., Mäkitie, A. A., Cohen, O. M., Pace‐Asciak, P., Vermorken, J. B., et al. (2023) · Cancers · doi:10.3390/cancers15071959 · Cited by 22
Prieto, V. D., Qian, S., Villarejo‐Campos, P., Meliga, C., González-Soares, S., Castellano, I. G., Jiménez-Galanes, S., García‐Arranz, M., Guadalajara, H., & García‐Olmo, D. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1104547 · Cited by 22
Galli, E., Fresa, A., Bellesi, S., Metafuni, E., Maiolo, E., Pansini, I., Frioni, F., Autore, F., Limongiello, M. A., Innocenti, I., et al. (2023) · European Journal Of Haematology · doi:10.1111/ejh.14052 · Cited by 23
McNerney, K. O., Hsieh, E. M., Shalabi, H., Epperly, R., Wolters, P. L., Hill, J. A., Gardner, R. A., Talleur, A. C., Shah, N. N., & Rossoff, J. E. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.10.006 · Cited by 21
The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL
Forsberg, M. H., Das, A., Saha, K., & Capitini, C. M. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s146309 · Cited by 22
Taraseviciute, A., Broglie, L. A., Phelan, R., Bhatt, N. S., Becktell, K., & Burke, M. J. (2019) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000001479 · Cited by 22
Management of T-Cell Engaging Immunotherapy Complications
Varadarajan, I., & Lee, D. W. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000377 · Cited by 22
Recent Advancements and Applications of Human Immune System Mice in Preclinical Immuno-Oncology
Curran, M., Mairesse, M., Matas‐Céspedes, A., Bareham, B. R., Pellegrini, G., Liaunardy, A., Powell, E., Sargeant, R., Cuomo, E. M., Stebbings, R., et al. (2019) · Toxicologic Pathology · doi:10.1177/0192623319886304 · Cited by 23
Futami, M., Suzuki, K., Kato, S., Ohmae, S., Tahara, Y., Nojima, M., Imai, Y., Mimura, T., Watanabe, Y., & Tojo, A. (2020) · PLoS ONE · doi:10.1371/journal.pone.0231896 · Cited by 22
Metadata
- Authors
- Teachey, D. T., Lacey, S. F., Shaw, P. A., Melenhorst, J. J., Maude, S. L., Frey, N., Pequignot, E., Gonzalez, V. E., Chen, F., Finklestein, J., Barrett, D. M., Weiss, S. L., Fitzgerald, J. C., Berg, R. A., Aplenc, R., Callahan, C., Rheingold, S. R., Zheng, Z., Rose-John, S., White, J. C., Nazimuddin, F., Wertheim, G., Levine, B. L., June, C. H., Porter, D. L., & Grupp, S. A.
- Affiliations
- Children's Hospital of Philadelphia (US)
- University of Pennsylvania (US)
- 10Institute of Biochemistry, CAU Kiel, Germany.
- Alexander T. Augusta Military Medical Center (US)
- Corresponding author
- Teachey, David T.
- ORCID
- Teachey, David T.
- Lacey, Simon F.
- Shaw, Pamela A.
- Melenhorst, J. Joseph
- Maude, Shannon L.
- Frey, Noelle
- Gonzalez, Vanessa E.
- Chen, Fang
- Barrett, David M.
- Weiss, Scott L.
- Fitzgerald, Julie C.
- Berg, Robert A.
- Aplenc, Richard
- Callahan, Colleen
- Rheingold, Susan R.
- Zheng, Zhaohui
- Wertheim, Gerald
- Levine, Bruce L.
- June, Carl H.
- Porter, David L.
- Grupp, Stephan A.
- Venue
- Cancer Discovery
- Published
- 2016-06-01
- Volume
- 6
- Issue
- 6
- Pages
- 664-679
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC5448406
- OpenAlex
- W2340435799
- Cited by
- 1,102
- References
- 35
- Citations by year
- 2026: 72 · 2025: 116 · 2024: 94 · 2023: 110 · 2022: 102 · 2021: 142 · 2020: 181 · 2019: 103 · 2018: 93 · 2017: 64 · 2016: 22
- FWCI
- 50.70
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA165206, R01CA102646, R01CA116660, R01CA193776, P30CA016520)
- National Institute of General Medical Sciences (K23GM110496)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- cytokine release syndrome, CAR T-cell therapy, acute lymphoblastic leukemia, CD19 CAR T cells, tisagenlecleucel, predictive biomarkers, cytokine profiling, interferon-gamma, interleukin-6, soluble gp130, C-reactive protein, ferritin, relapsed/refractory leukemia, toxicity prediction
- MeSH terms
- Adolescent, Adult, Aged, Child, Child, Preschool, Female, Humans, Immunotherapy, Male, Middle Aged, Phenotype, Prognosis, Receptors, Antigen, T-Cell, ROC Curve, Severity of Illness Index, Tumor Lysis Syndrome, Biomarkers, Cytokines, Treatment Outcome, Antigens, CD19, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Young Adult, Antibodies, Monoclonal, Humanized, Cell- and Tissue-Based Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
